Seres Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 126.47 million compared to USD 1.22 million a year ago. Net income was USD 46.55 million compared to net loss of USD 64.74 million a year ago. Basic earnings per share from continuing operations was USD 0.36 compared to basic loss per share from continuing operations of USD 0.7 a year ago. Diluted earnings per share from continuing operations was USD 0.36 compared to diluted loss per share from continuing operations of USD 0.7 a year ago.
For the six months, revenue was USD 125.95 million compared to USD 2.71 million a year ago. Net loss was USD 24.62 million compared to USD 121.36 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 1.32 a year ago. Diluted loss per share from continuing operations was USD 0.19 compared to USD 1.32 a year ago.